Results 31 to 40 of about 18,888 (217)

A Case Report of Pemphigoid Nodularis as Masquerader of Neurotic Excoriations

open access: yesInternational Journal of Dermatology and Venerology, 2020
. Introduction:. Pemphigoid nodularis is a rare clinical variant of bullous pemphigoid characterized by both prurigo nodularis-like lesions and pemphigoid-like blisters.
Chee Hian Tan, Hong Liang Tey
doaj   +1 more source

Pemphigoid gestationis [PDF]

open access: yesBMJ Case Reports, 2011
A 39-year-old woman in the 39th week of her fifth pregnancy presented with severe itching. In recent weeks she had developed an increasingly itchy rash on her trunk and arms. Upon examination we observed multiple erythematous plaques and vesicles. Histological examinations of two skin biopsies confirmed the diagnosis of pemphigoid gestationis.
Marije van de Water   +3 more
openaire   +3 more sources

Mucous Membrane Pemphigoid with Tracheal Involvement

open access: yesCase Reports in Pulmonology, 2016
34-year-old African American female with history of pemphigoid presented with hemoptysis. Patient was found to have mucous membrane pemphigoid involving the oropharynx and extending to trachea, till just above main stem carina. Four other cases described
Arash Minaie, Salim R. Surani
doaj   +1 more source

Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review

open access: yesSAGE Open Medical Case Reports, 2022
Bullous pemphigoid is an acquired autoimmune blistering dermatosis that is commonly associated with high morbidity and mortality. New-onset bullous pemphigoid following vaccinations has rarely been reported in the literature.
Vincent Wan   +3 more
doaj   +1 more source

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

open access: yesSAGE Open Medical Case Reports, 2023
Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj   +1 more source

Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

open access: yesFrontiers in Immunology, 2022
Chronic blistering at the skin and/or mucous membranes, accompanied by a varying degree of inflammation, is the clinical hallmark of pemphigoid diseases that impose a major medical burden.
Saeedeh Ghorbanalipoor   +19 more
doaj   +1 more source

The Complex Role of IL‐13 in Bullous Pemphigoid: New Insights From a Retrospective Cohort Study

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, primarily affecting the elderly. The role of interleukin‐13 (IL‐13) in BP pathogenesis remains unclear, particularly regarding its potential as a therapeutic target.
Marwan Dawood   +6 more
wiley   +1 more source

The Rare Presentation of Deep Dermatophytosis‐Trichophyton in an Immunosuppressed Patient

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Dermatophytes typically cause superficial skin infections characterized by an active border. However, they can present atypically invading deeper in immunocompromised patients. We present a case of a 72‐year‐old woman with bullous pemphigoid who had received oral prednisolone for 3 months and developed umbilicated papules.
Jidapa Triwatcharikorn   +3 more
wiley   +1 more source

Acquired Haemophilia Occurring in Association With Bullous Pemphigoid

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Acquired haemophilia A (AHA) is a rare condition due to neutralizing antibodies against Factor VIII and can result in severe bleeding manifestations. The association of AHA with bullous pemphigoid (BP) is rare, most frequently observed in the elderly, and has been attributed to cross‐reactive antibodies targeting Factor VIII and BPAG2 protein.
Wen Yang Benjamin Ho   +3 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy